TRANSLATIONAL
Utilizing next generation sequencing data to enhance the prediction of cardiac toxicity risk during therapy for AML and leading novel CAR target discovery work in pediatric AML using proteogenomic approaches to identify targets on the AML blast surfaceome.
​Lu C, Glisovic-Aplenc T, Bernt KM, Nestler K, Cesare J, Cao L, Lee H, Fazelinia H, Chinwalla A, Xu Y,
Shestova O, Xing Y, Gill S, Li M, Garcia B, Aplenc R. Longitudinal Large-Scale Semiquantitative
Proteomic Data Stability Across Multiple Instrument Platforms. J Proteome Res. 2021 Nov
5;20(11):5203-5211. PubMed PMID: 34669412.
Pan Y, Kadash-Edmondson KE, Wang R, Phillips J, Liu S, Ribas A, Aplenc R, Witte ON, Xing Y. RNA
Dysregulation: An Expanding Source of Cancer Immunotherapy Targets. Trends Pharmacol Sci. 2021
Apr;42(4):268-282. PubMed Central PMCID: PMC8761020.
​
Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, Toepfer CN, GetzK, Gorham J, Patel P, Ito K, Willcox JA, Arany Z, Li J, Owens AT, Govind R, Nuñez B, Mazaika E,Bayes-Genis A, Walsh R, Finkelman B, Lupon J, Whiffin N, Serrano I, Midwinter W, Wilk A, Bardaji A,Ingold N, Buchan R, Tayal U, Pascual-Figal DA, de Marvao A, Ahmad M, Garcia-Pinilla JM, PantazisA, Dominguez F, John Baksi A, O'Regan DP, Rosen SD, Prasad SK, Lara-Pezzi E, Provencio M, LyonAR, Alonso-Pulpon L, Cook SA, DePalma SR, Barton PJR, Aplenc R, Seidman JG, Ky B, Ware JS,Seidman CE. Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation.2019 Jul 2;140(1):31-41. PubMed Central PMCID: PMC6613726.
​
Glisovic-Aplenc T, Gill S, Spruce LA, Smith IR, Fazelinia H, Shestova O, Ding H, Tasian SK, Aplenc R,
Seeholzer SH. Improved surfaceome coverage with a label-free nonaffinity-purified workflow.
Proteomics. 2017 Apr;17(7) PubMed Central PMCID: PMC5518111.